CYP2D6
Also known as: 2D6GENO
Use
The CYP2D6 test assesses genetic risk of abnormal drug metabolism for CYP2D6 substrates and may aid in the selection and dose planning of drugs that are metabolized by CYP2D6. Variants in the CYP2D6 gene can influence pharmacokinetics and predict nonstandard dose requirements, potential therapeutic failure, or adverse reactions to drugs such as antidepressants, antipsychotics, and others impacted by the cytochrome P450 2D6 isozyme.
Special Instructions
Informed consent is required for genetic testing, particularly for New York state patients. Counseling and consultation with a medical provider are recommended. Note that the test results do not replace the need for therapeutic drug monitoring.
Limitations
The test is designed to detect targeted CYP2D6 variants, making assumptions about allele content for predictions. The test cannot identify a combination of gene deletion (*5) and duplication and may not distinguish between heterozygous and homozygous mutations. Diagnostic errors can also occur due to rare sequence variations. The assay is not intended to replace clinical drug monitoring or therapeutic drug monitoring.
New York Approved
Methodology
PCR-based (PCR)
Biomarkers
LOINC Codes
- 79715-9
- 31208-2
- 40425-1
- 50398-7
- 11526-1
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or B)
Storage Instructions
Preferred transport temp: Refrigerated
Causes for Rejection
Plasma or serum. Specimens collected in sodium heparin or lithium heparin. Frozen specimens in glass collection tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 3 days |
| Refrigerated | 1 week |
| Frozen | 1 month |